Who is sponsoring NCT05208866?

NCT05208866 is sponsored by Palladio Biosciences.

What condition does NCT05208866 study?

NCT05208866 studies Polycystic Kidney Disease, Adult.

What is the status of NCT05208866?

NCT05208866 is currently TERMINATED.

Last reviewed 2023-05-12 · How we verify

Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

NCT05208866 PHASE3 TERMINATED Results posted

This is a Phase 3, open-label, roll-over study to demonstrate the continued hepatic and non-hepatic safety and renal efficacy of lixivaptan in participants with ADPKD who previously experienced abnormal liver chemistry test results while treated with tolvaptan, were permanently discontinued from the drug for that reason, and subsequently completed study PA-ADPKD-303, the open-label lead-in study with lixivaptan.

Details

Lead sponsor	Palladio Biosciences
Phase	PHASE3
Status	TERMINATED
Enrolment	1
Start date	Thu Feb 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jul 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Polycystic Kidney Disease, Adult

Interventions

Lixivaptan

Countries

United States